Fusion polypeptides and vaccines
AssigneeCeva Sante Animale
InventorTakanori Sato
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
Claims14
A polypeptide comprising a cell-membrane addressing peptide directly operably linked to a heterologous antigenic polypeptide, wherein the cell membrane addressing peptide is located N-terminally, and wherein the sequence of said cell membrane addressing peptide is 50 amino acids or less in length and contains SEQ ID NO:
- 1 or a sequence having at least 90% identity to SEQ ID NO:
- 1.
A polypeptide comprising a signal peptide directly operably linked to an antigenic polypeptide from a Porcine Circovirus Type 2 (PCV2) virus, wherein the signal peptide is located N-terminally and the antigenic polypeptide is located C-terminally, and wherein the signal peptide consists of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.